PP_1170x120_10-25-21

Christi Shaw

Lilly’s Emgality gets FDA approval for the preventive treatment of migraine in adults

Lilly’s Emgality gets FDA approval for the preventive treatment of migraine in adults

INDIANAPOLIS — Eli Lilly and Co. announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults. Emgality offers a once-monthly, self-administered, subcutaneous injection. Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients. Emgality will be available to patients

Adheris Health